Back to top

Agios Pharmaceuticals, Inc. (AGIO)

(Delayed Data from NSDQ)

$46.11 USD


-1.03 (-2.18%)

Updated Sep 20, 2021 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.60%
5Strong Sell3.32%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 17% (208 out of 252)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Company Summary

Cambridge, MA-based Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on development of treatments for rare genetic metabolic disorders, a subset of orphan genetic metabolic diseases.
The company is focused on expanding its genetically defined disease portfolio, especially the development of its lead pipeline candidate, mitapivat. The rare genetic diseases candidate, mitapivat, is being developed for treating patients with pyruvate kinase (PK) deficiency. Regulatory applications seeking approval for the candidate have been filed in the United States (FDA decision on February 17, 2022) and EU in June 2021. The company is also developing mitapivat for treating ...

General Information

Agios Pharmaceuticals, Inc.



Phone: 617-649-8600

Fax: NA



Industry Medical - Products
Sector Medical
Fiscal Year End December
Last Reported Quarter 6/30/2021
Next EPS Date 11/4/2021

EPS Information

Current Quarter EPS Consensus Estimate -1.61
Current Year EPS Consensus Estimate 25.60
Estimated Long-Term EPS Growth Rate NA
Next EPS Report Date 11/4/2021

Price and Volume Information

Zacks Rank Premium
Yesterday's Close 47.14
52 Week High 62.16
52 Week Low 32.47
Beta 1.58
20 Day Moving Average 406,515.84
Target Price Consensus 64.57


% Price Change
4 Week 9.12
12 Week -16.89
YTD 8.79
% Price Change Relative to S&P 500
4 Week 9.33
12 Week -19.75
YTD -7.82
Share Information
Shares Outstanding (millions) 58.95
Market Capitalization (millions) 2,778.97
Short Ratio NA
Last Split Date NA
Dividend Information
Dividend Yield 0.00%
Annual Dividend $0.00
Payout Ratio NA
Change in Payout Ratio NA
Last Dividend Payout / Amount NA / $0.00

Fundamental Ratios

P/E (F1) 1.84
Trailing 12 Months NA
PEG Ratio NA
EPS Growth
vs. Previous Year -3.82%
vs. Previous Quarter -3.82%
Sales Growth
vs. Previous Year 24.28%
vs. Previous Quarter 26.91%
Price Ratios
Price/Book 1.61
Price/Cash Flow NA
Price / Sales 13.68
6/30/21 -30.24
3/31/21 -40.48
12/31/20 -63.45
6/30/21 -24.18
3/31/21 -28.93
12/31/20 -37.02
Current Ratio
6/30/21 28.07
3/31/21 24.40
12/31/20 6.74
Quick Ratio
6/30/21 28.07
3/31/21 24.40
12/31/20 6.59
Operating Margin
6/30/21 NA
3/31/21 NA
12/31/20 -161.11
Net Margin
6/30/21 NA
3/31/21 NA
12/31/20 -161.11
Pre-Tax Margin
6/30/21 -425.96
3/31/21 -287.82
12/31/20 -161.11
Book Value
6/30/21 29.21
3/31/21 37.30
12/31/20 5.76
Inventory Turnover
6/30/21 0.43
3/31/21 0.30
12/31/20 0.24
6/30/21 0.00
3/31/21 0.00
12/31/20 0.00
Debt to Capital
6/30/21 0.01
3/31/21 0.01
12/31/20 0.08